CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.

The CD40-CD40 ligand (CD40L) interaction is a key event in the initiation of an adaptive immune response, and as such the therapeutic value of CD40L blockade has been studied in many experimental models of tissue transplantation and autoimmune disease. In rodents, transplantation of allogeneic tissu...

Full description

Bibliographic Details
Main Authors: Honey, K, Cobbold, S, Waldmann, H
Format: Journal article
Language:English
Published: 1999
_version_ 1797058864310386688
author Honey, K
Cobbold, S
Waldmann, H
author_facet Honey, K
Cobbold, S
Waldmann, H
author_sort Honey, K
collection OXFORD
description The CD40-CD40 ligand (CD40L) interaction is a key event in the initiation of an adaptive immune response, and as such the therapeutic value of CD40L blockade has been studied in many experimental models of tissue transplantation and autoimmune disease. In rodents, transplantation of allogeneic tissues under the cover of anti-CD40L Abs has resulted in prolonged graft survival but not tolerance. In this report, we show that failure to induce tolerance probably results from the inability of anti-CD40L Abs to prevent graft rejection elicited by the CD8+ T cell subset. When the CD8+ T cell population is controlled independently, using anti-CD8 Abs, then tolerance is possible. Transplantation tolerance induced by anti-CD4 mAbs can often be associated with dominant regulation, manifested as infectious tolerance and linked suppression, both of which are mediated by CD4+ T cells. We show here that CD4+ T cells rendered tolerant using anti-CD40L therapy exhibit the same regulatory property of linked suppression, as demonstrated by their ability to accept grafts expressing third party Ags only if they are expressed in conjunction with the tolerated Ags. This observation of linked suppression reveals a hitherto undocumented consequence of CD40L blockade that suggests the tolerant state is maintained by a dominant regulatory mechanism. Our results suggest that, although anti-CD40L Abs are attractive clinical immunotherapeutic agents, additional therapies to control aggressive CD8+ T cell responses may be required.
first_indexed 2024-03-06T19:56:23Z
format Journal article
id oxford-uuid:25be9fc5-620e-4de0-a4ad-ffdbec80a627
institution University of Oxford
language English
last_indexed 2024-03-06T19:56:23Z
publishDate 1999
record_format dspace
spelling oxford-uuid:25be9fc5-620e-4de0-a4ad-ffdbec80a6272022-03-26T11:57:16ZCD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:25be9fc5-620e-4de0-a4ad-ffdbec80a627EnglishSymplectic Elements at Oxford1999Honey, KCobbold, SWaldmann, HThe CD40-CD40 ligand (CD40L) interaction is a key event in the initiation of an adaptive immune response, and as such the therapeutic value of CD40L blockade has been studied in many experimental models of tissue transplantation and autoimmune disease. In rodents, transplantation of allogeneic tissues under the cover of anti-CD40L Abs has resulted in prolonged graft survival but not tolerance. In this report, we show that failure to induce tolerance probably results from the inability of anti-CD40L Abs to prevent graft rejection elicited by the CD8+ T cell subset. When the CD8+ T cell population is controlled independently, using anti-CD8 Abs, then tolerance is possible. Transplantation tolerance induced by anti-CD4 mAbs can often be associated with dominant regulation, manifested as infectious tolerance and linked suppression, both of which are mediated by CD4+ T cells. We show here that CD4+ T cells rendered tolerant using anti-CD40L therapy exhibit the same regulatory property of linked suppression, as demonstrated by their ability to accept grafts expressing third party Ags only if they are expressed in conjunction with the tolerated Ags. This observation of linked suppression reveals a hitherto undocumented consequence of CD40L blockade that suggests the tolerant state is maintained by a dominant regulatory mechanism. Our results suggest that, although anti-CD40L Abs are attractive clinical immunotherapeutic agents, additional therapies to control aggressive CD8+ T cell responses may be required.
spellingShingle Honey, K
Cobbold, S
Waldmann, H
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
title CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
title_full CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
title_fullStr CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
title_full_unstemmed CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
title_short CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
title_sort cd40 ligand blockade induces cd4 t cell tolerance and linked suppression
work_keys_str_mv AT honeyk cd40ligandblockadeinducescd4tcelltoleranceandlinkedsuppression
AT cobbolds cd40ligandblockadeinducescd4tcelltoleranceandlinkedsuppression
AT waldmannh cd40ligandblockadeinducescd4tcelltoleranceandlinkedsuppression